William Blair Hires Head of Biopharma Investment Banking, based in New York
William Blair announced today the expansion of the firm’s Healthcare team with the addition of Michael Allwin as managing director and head of Biopharma investment banking. Based in New York, Allwin will lead the firm’s global efforts to provide comprehensive advisory services to public and private biopharma companies across all stages of development as well as financial sponsors and venture firms focused on the sector.
“Michael will play a critical role in further expanding our biopharma industry platform, while enhancing our coverage of this fast-paced and complex vertical,” said Steve Tole, managing director and head of Healthcare investment banking at William Blair. “He brings a strong reputation as an advisor who provides sophisticated capital-raising solutions and strategic advice with robust client service to companies and investors that are driving innovations across the biopharma sector.”
Allwin joins from Truist Securities, where he was managing director and head of biopharma investment banking. His nearly 15 years of experience in biopharma also includes investment banking roles at Credit Suisse, RBC Capital Markets, and Deutsche Bank, with extensive experience in deal origination and execution of M&A and equity and equity-linked transactions, IPOs, follow-ons, private placements, debt securities, PIPEs, and venture capital funding. He received his B.A. in political science and economics from Bucknell University.
